Trials & Filings

MannKind Resubmits Afrezza

New NDA covers glycemic control in Types 1 and 2 diabetes

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

MannKind Corp. has resubmitted the NDA for Afrezza (insulin human [rDNA origin]) Inhalation Powder to the FDA. The NDA seeks approval for the marketing and sale of Afrezza with an indication to improve glycemic control in adults with type 1 or type 2 diabetes. The resubmission is based on the entire data set from the Afrezza clinical development program and particularly the positive results from two recent Phase III trials, one in patients with type 1 diabetes (study 171) and one in patients wi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters